CClinicalTrials.gg
CompletedNCT06718712Updated Dec 11, 2024

Resistance Exercise Volume and Hypertrophic Response Variability in Elderly

An interventional study of Lower body resistance training in Aging and Muscle Hypertrophy, sponsored by University of Sao Paulo General Hospital. Completed at 1 site in Brazil. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 6 years 8 months after the study started (first participant enrolled Apr 2018, registered Dec 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The study aimed to investigate the effects of resistance training volume manipulation on whole muscle hypertrophy among non-responders and responders to a low resistance training dose (single-set).

Read the detailed description

The magnitude of muscle hypertrophy in response to resistance training (RT) is highly variable between individuals (response heterogeneity). Manipulations in RT variables may modulate RT-related response heterogeneity; yet, this remains to be determined.

02

Conditions studied

  • Aging
  • Muscle Hypertrophy

Browse trials for

Keywords

  • aging
  • muscle mass
  • muscle strength
  • resistance exercise
  • sets
03

In context

Hypertrophy

656 studies on the registry are indexed under Hypertrophy; 87 are open to participants now.

This study's enrollment of 102 is above the median of 50 across 460 interventional studies indexed under Hypertrophy.

Browse Hypertrophy studies →

Lead sponsor

University of Sao Paulo General Hospital is the lead sponsor of 595 studies on the registry; 98 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 60 years and older
  • not engaged in regular resistance and/or aerobic training for at least six months before the intervention

Exclusion criteria

Exclusion Criteria:

  • diagnosed type I diabetes mellitus
  • arrhythmia
  • noncontrolled hypertension
  • any major orthopedic musculoskeletal condition
  • use of any dietary supplement or drug with potential anabolic effects
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Single set

    One set of unilateral knee-extension exercise of 8-15 RM with a 60-90 s interval.

    Other: Lower body resistance training

  • Experimental
    Four sets

    Four sets of unilateral knee-extension exercise of 8-15 RM with a 60-90 s interval between sets.

    Other: Lower body resistance training

Interventions

  • OtherLower body resistance training

    The RT protocol was performed using a unilateral knee-extension machine. To reduce potential sources of bias to exercise order, subjects alternated the starting leg for each training session.

06

What researchers measure

Primary outcomes

  1. Quadriceps muscle cross-sectional area

    Quadriceps muscle CSA was obtained through magnetic resonance imaging.

    Time frame: 10 weeks

Secondary outcomes

  1. Maximum dynamic strength

    Unilateral quadriceps 1-RM of both legs were assessed on a knee-extension machine

    Time frame: 10 weeks

Other outcomes

  1. Dietary assessment

    Dietary assemment using the USDA Automated Multiple-Pass Method

    Time frame: Before intervention

  2. Mass spectrometry

    Mass spectrometry metabolomics

    Time frame: 10 weeks

  3. Skeletal muscle RNA-sequencing

    RNA sequencing using an Illumina NovaSeq Platform with a standard paired-end 150 bp (PE150) dual indexing protocol

    Time frame: 10 weeks

  4. Muscle protein measures

    Upstream binding factor (UBF) muscle protein was quantified by Simple Western capillary immunoassay.

    Time frame: 10 weeks

  5. Muscle protein measures

    v-Myc Avian Myelocytomatosis Viral Oncogene Homolog (c-Myc) muscle protein was quantified by Simple Western capillary immunoassay.

    Time frame: 10 weeks

  6. Muscle protein measures

    Frizzled class receptor 1 (Frizzled-1) muscle protein was quantified by Simple Western capillary immunoassay.

    Time frame: 10 weeks

  7. Muscle protein measures

    ribosomal protein L3 (rpL3) muscle protein was quantified by Simple Western capillary immunoassay.

    Time frame: 10 weeks

07

Study locations

1 site
  • University of Sao Paulo
    Sao Paulo, SP 05508-030, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06718712
Lead sponsor
University of Sao Paulo General Hospital
Collaborators
University of Sao Paulo
Responsible party
Hamilton Augusto Roschel da Silva (Principal Investigator, University of Sao Paulo) — Principal investigator
First posted
Dec 5, 2024
Start date
Apr 1, 2018
Primary completion
Dec 20, 2018
Completion
Dec 20, 2018
Last update
Dec 11, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion